Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand

Cancer Science

Volumn 97, Issue 10, 2006, Pages 1093-1098

  Oka, Natsuo ^a   Tanimoto, Shuji ^a   Taue, Ryuichi ^a   Nakatsuji, Hiroyoshi ^a   Kishimoto, Tomoteru ^a   Izaki, Hirofumi ^a   Fukumori, Tomoharu ^a   Takahashi, Masayuki ^a   Nishitani, Masaaki ^a   Kanayama, Hiro Omi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL PROTECTION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 3; CASPASE 9; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 33748305554     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00294.x     Document Type: Article

References (28)

1. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998; 254: 439-59.
2. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-8.
3. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256: 58-66.
4. Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-63.
5. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-41.
6. French LE, Tschopp J. The TRAIL to selective tumor death. Nat Med 1999; 5: 146-7.
7. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277: 768.
8. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-40.
9. Muhlenbeck F, Haas E, Schwenzer R et al. TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways. J Biol Chem 1998; 273: 33091-8.
10. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20: 2122-33.
11. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-90.
12. Kennedy SG, Wagner AJ, Conzen SD et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 1997; 11: 701-13.
13. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-41.
14. Cheng JQ, Godwin AK, Bellacosa A et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-71.
15. Takenaka Y, Fukumori T, Yoshii T et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol 2004; 24: 4395-406.
16. Kim EJ, Suliman A, Lam A, Srivastava RK. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand. Int J Oncol 2001; 18: 187-94.
17. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-9.
18. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
19. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
20. Wajant H, Haas E, Schwenzer R et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J Biol Chem 2000; 275: 24357-66.
21. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-97.
22. Datta SR, Brunet A, Greenberg ME. Cellular survival: A play in three Akts. Genes Dev 1999; 13: 2905-27.
23. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
24. Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-21.
25. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-5.
26. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
27. Kops GJ, Burgering BM. Forkhead transcription factors: New insights into protein kinase B (c-akt) signaling. J Mol Med 1999; 77: 656-65.
28. Uslu R, Borsellino N, Frost P et al. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997; 3: 963-72.